CELLINK and Atelerix team up to enable the shipping at room temperature of fragile 3D bioprinted constructs by the world’s bioprinting community
CELLINK and Atelerix announced today a partnership to bring to market Atelerix’s portfolio of innovative hydrogel biological encapsulation products, which preserve fragile biological samples for shipping at room temperature. Conventional shipping methods often involve storing cells and tissues in liquid nitrogen or dry ice, which requires a freeze-thaw process notorious for damaging biological material. Therefore, the global bioprinting community will greatly benefit from Atelerix products that allow for room-temperature storage and shipping of sensitive primary cells, iPSC-derived cells, multicellular models and especially cell-laden bioprinted constructs, such as those manufactured with CELLINK’s range of innovative 3D bioprinters.
“Ultimately, it’s the simple things that make a difference,” says Dr. Himjyot Jaiswal, CELLINK’s Scientific Team Lead for Tissue Engineering and Cell Biology. “This technology will enable scientists to ‘lower the barrier’ for initiating lab-to-lab collaborations that require ‘living material’ to be moved from one researcher to another.”
Atelerix’s range of innovative products, including BeadReady™ (used for cells in suspension), WellReady™ (used for plated cells and cell-laden bioprinted constructs) and TissueReady™ (used for tissue samples and larger cell-laden bioprinted constructs), will be available for purchase from CELLINK, so that the research community may procure all their bioprinting requirements in one place.
“The news of two of the most exciting and innovative life science companies coming together to enable the scientific community to ship biofabricated 3D models is incredibly important,” says Steve Swioklo, CSO of Atelerix. “The manufacture of cell-laden bioprinted constructs is one of the fastest growing application areas in today’s life science industry, but it is hampered by the need to ship bioprinted tissues and models from one laboratory to another whilst preserving cell viability and fine structure integrity. Atelerix’s products now make that possible.”
CELLINK CSO Dr. Itedale Namro Redwan agrees, “We are very pleased to announce this very important partnership with Atelerix. The technology that they provide for shipping 3D bioprinted constructs, tissues and cells at room temperature will have a major impact on how collaborations between labs are executed—and even on how tissues and organs are transported from lab-to-clinic or clinic-to-clinic. We see the Atelerix range of products complementing our bioprinter and bioink portfolio well.”
For further information, please contact:
CELLINK
Erik Gatenholm, CEO
Phone (Sweden): +46 73 267 00 00
Phone (US): +1 (650) 515 5566
Email: eg@cellink.com
Gusten Danielsson, CFO
Phone (Sweden): +46 70 991 86 04
Phone (US): +1 (857) 332 2138
Email: gd@cellink.com
Arvid Wallgrens Backe 20
413 46 Gothenburg
Sweden
Atelerix
Mick Mclean, CEO
Phone (HQ): +44 191 580 6181
Phone (Mob.): +44 7817 44 44 85
Email: mick.mclean@atelerix.co.uk
Sanj Kumar, CBO
Phone (HQ): +44 191 580 6181
Phone (Mob.): +44 7860 89 29 44
Email: sanj.kumar@atelerix.co.uk
The Biosphere, Draymans Way
Newcastle Helix
Newcastle upon Tyne, NE4 5BX, UK
About CELLINK
CELLINK is the leading bio-convergence company and a global provider of technologies, products and services to create, understand and master biology. With a focus on the areas of bioprinting, biosciences and industrial solutions, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 60 countries, and have been cited in more than 700 publications. CELLINK is creating the future of medicine. Visit cellink.com to learn more. CELLINK is listed on the Nasdaq Stockholm Main Market under CLNK B.
About Atelerix
Founded in 2017, Atelerix is a biotech company based in the UK with a novel technology that enables the shipment of cells at room temperature, thus avoiding the problems with cryo-logistics and particularly damage caused to cells by freeze-thaw processes. Its application areas are many - from research projects, to protecting plates of cells for drug discovery, to the shipment of cellular therapies in blood bags. When using our hydrogel, to encapsulate cells, all these application areas benefit from the technology, as the gel physically protects the cells and ensures they remain viable throughout transportation. Visit Atelerix.co.uk to learn more.
